Nine months after GlaxoSmithKline's bribery scandal first ignited a corruption hunt among Big Pharma companies in China, drugmakers--GSK excepted--are returning to the strong emerging-markets growth they're accustomed to in the country.
Just days after GlaxoSmithKline announced it would open a new R&D lab and invest more than $200 million in Africa, Sanofi CEO Chris Viehbacher is affirming his country's devotion to Africa, too.
GlaxoSmithKline has long been a leader in producing vaccines for Africa, but now it's going one step further. The British pharma will tailor a portfolio of meds to address specific health needs on the continent and increase the registration of drugs and vaccines it already has, the company said this week.
The FDA has again issued an import alert against a plant owned by Canadian generic drugmaker Apotex, this one in India. The last time the agency took that kind of action, Apotex took the matter to international authorities in a North American Free Trade Agreement complaint.
Actavis has bagged its latest catch. Fresh off last month's deal to buy Forest Laboratories in a $25 billion deal, the generics maker forked over a much smaller amount--$100 million--to buy a small generics company in Thailand.
GlaxoSmithKline is making a deeper commitment to consumer healthcare sales in Indonesia but is selling off a manufacturing plant there to do that.
GlaxoSmithKline will spend £100 million on a handful of plants in Africa as part of a campaign to help African countries build the facilities and know-how to manufacture the drugs they need at costs they can bear.
Lots of drugmakers see Africa as a market that over time can produce some substantial business. But GlaxoSmithKline is not just manufacturing and selling drugs there. It is going one better with a new "open lab" R&D facility to let African researchers work on the drugs needed by Africans for noncommunicable diseases.
AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population.
In the nearly 40 years since scientists first nailed down the Ebola virus, drug researchers have yet to commercialize an effective therapy for the deadly disease, a problem made worse by a lack of commercial promise and the relative rarity of outbreaks.